Related Experiment Video
Updated: Feb 11, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells
Wei Li1,2, Ling Xu1,2, Xiaofang Che1,2
1Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.
Background:
Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood. Here we examined whether ER-c-Src-HER2 complex formation is involved in tamoxifen resistance.
Methods:
MTT and colony formation assays were used to measure cell viability and proliferation. Western blot was used to detect protein expression and protein complex formations were detected by immunoprecipitation and immunofluorescence. SiRNA was used to examine the function of HER2 in of BT474 cells. An in vivo xenograft animal model was established to examine the role of c-Cbl in tumor growth.
Results:
MTT and colony formation assay showed that BT474 cells are resistant to tamoxifen and T47D cells are sensitive to tamoxifen. Immunoprecipitation experiments revealed ER-c-Src-HER2 complex formation in BT474 cells but not in T47D cells. However, ER-c-Src-HER2 complex formation was detected after overexpressing HER2 in T47D cells and these cells were more resistant to tamoxifen. HER2 knockdown by siRNA in BT474 cells reduced ER-c-Src-HER2 complex formation and reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was also disrupted and tamoxifen resistance was reversed in BT474 cells by the c-Src inhibitor PP2 and HER2 antibody trastuzumab. Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was disrupted by overexpression of c-Cbl but not by the c-Cbl ubiquitin ligase mutant. In addition, c-Cbl could reverse tamoxifen resistance in BT474 cells, but the ubiquitin ligase mutant had no effect. The effect of c-Cbl was validated in BT474 tumor-bearing nude mice in vivo. Immunofluorescence also revealed ER-c-Src-HER2 complex formation was reduced in tumor tissues of nude mice with c-Cbl overexpression.
Conclusions:
Our results suggested that c-Cbl can reverse tamoxifen resistance in HER2-overexpressing breast cancer cells by inhibiting the formation of the ER-c-Src-HER2 complex.
Insights
Tamoxifen resistance in breast cancer can be reversed by targeting the ER-c-Src-HER2 complex. Overexpression of c-Cbl inhibits this complex, restoring tamoxifen sensitivity in HER2-positive cells.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tamoxifen is a primary treatment for estrogen receptor (ER)-positive breast cancer.
- Tamoxifen resistance is a significant clinical challenge, and its mechanisms remain incompletely understood.
- This study investigates the role of the ER-c-Src-HER2 complex in tamoxifen resistance.
Purpose of the Study:
- To determine if the formation of the ER-c-Src-HER2 complex contributes to tamoxifen resistance in breast cancer.
- To explore the potential of targeting this complex to overcome tamoxifen resistance.
Main Methods:
- Cell viability and proliferation assays (MTT, colony formation).
- Protein expression and complex detection (Western blot, immunoprecipitation, immunofluorescence).
- Gene knockdown (siRNA), drug inhibition (PP2, trastuzumab, nystatin), and in vivo xenograft models.
Main Results:
- Tamoxifen-resistant (BT474) and sensitive (T47D) cell lines were identified.
- ER-c-Src-HER2 complex formation was present in resistant cells and induced in sensitive cells upon HER2 overexpression.
- HER2 knockdown, c-Src inhibition, trastuzumab, and c-Cbl overexpression reversed tamoxifen resistance by disrupting the complex.
Conclusions:
- The ER-c-Src-HER2 complex is implicated in tamoxifen resistance in HER2-overexpressing breast cancer.
- c-Cbl can reverse tamoxifen resistance by inhibiting the formation of this complex.
- Targeting the ER-c-Src-HER2 complex presents a potential therapeutic strategy.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
09:22Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish
Published on: April 25, 2017
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Reversible and Irreversible Processes
Diode: Reverse bias
Receptor-mediated Endocytosis